Ceredase in the treatment of type 1 Gaucher's disease

Hallam L, Bryant J
Record ID 31998008704
Authors' objectives:

The report aims to determine the cost effectiveness of the proposal to use Ceredase as a replacement therapy in appropriate patients with Gaucher's disease.

Authors' results and conclusions: Studies show that Ceredase, administered in a low-dose high-frequency protocol, is safe and effective in reversing the manifestations of Gaucher's disease. Ceredase is currently the treatment of choice for patients with symptomatic Gaucher's disease. New developments, such as gene therapy and synthetically produced enzyme, may prove effective and less costly in the future.
Authors' recommendations: The authors conclude that the proposal would be beneficial but the cost would be high, and that more work is needed to determine the optimum dose.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Costs and Cost Analysis
  • Glucosylceramidase
  • Gaucher Disease
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.